MedTrace Logo

Low Dose Dexmedetomidine as a Postoperative Pain Adjunct

NCT06067893 · Status: ENROLLING_BY_INVITATION · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2025-12-22

No results posted yet for this study

Summary

This randomized controlled trial examines whether the addition of a low-dose dexmedetomidine infusion to our current multimodal pain management plan decreases narcotic consumption and reduces side effects in adolescent patients undergoing posterior spinal fusion for idiopathic scoliosis.

Conditions

  • Spinal Fusion
  • Adolescent Idiopathic Scoliosis

Interventions

DRUG

Dexmedetomidine

Patient receives dexmedetomidine for 48 hours post-operatively

DRUG

Normal Saline

Patient receives normal saline for 48 hours post-operatively

Sponsors & Collaborators

  • Nichole Doyle

    lead OTHER

Principal Investigators

  • Nichole M Doyle, MD · Children's Mercy Hospital Kansas City

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2026-07-31
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06067893 on ClinicalTrials.gov